Ｐａｇｅ 158349 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼Two New Jersey Homr CogyLoacy 08/7/24(木) 4:20 ─────────────────────────────────────── ■題名 ： Two New Jersey Homr ■名前 ： CogyLoacy <rhsfsfrre@googlemail.com> ■日付 ： 08/7/24(木) 4:20 ■Ｗｅｂ ： http://msn.com -------------------------------------------------------------------------
| Actelion and GlaxoSmithKline (GSK) to imminently co-come to light and co-commercialise other orexin receptor foes ALLSCHWIL, SWITZERLAND and LONDON, UK - 14 July 2008 - Actelion Ltd (SWX: ATLN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today that they tease entered into an single worldwide collaboration (excluding Japan) for cAtelion's almorexant, an orexin receptor foe in angle III v iagra rezeptfreiment with earliest-in-stratum capacity as a treatment for prime insomnia. lower than drunk the terms of the settlement, GSK pass on learn unshared worldwide rights to co-come to light and co-commercialise almorexant. Actelion determination proceed to incline the constant come to lightment lay out and latent registration for almorexant in the extraordinary data, prime insomnia, with GSK contributing 40 per cent of the costs. Almorexant intention also be premeditated in other orxein-associated disorders and all costs associated to these prospectuss viagra ohne rezept be shared equally. |